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1. Introduction 
Renal cell carcinoma (RCC) was the 9th commonest malignancy in Europe in 2008 [1] with 
an estimated 88400 new cases and 39300 deaths [2] making it the most lethal urological 
malignancy. Over the last 2 decades there has been a significant increase in the incidence of 
small renal masses (SRMs) at diagnosis often as an incidental finding as a result of 
abdominal imaging for the investigation of pain or other abdominal symptoms [3]. This has 
resulted in a stage migration to smaller and lower stage lesions in asymptomatic patients [4]. 
Many of these SRMs are slow growing and of low malignant potential although the precise 
natural history remains unclear [5]. The rate of radiographic growth in most series which 
have followed renal masses usually for 3 years is between 0 and 0.86 cm/yr with a meta-
analysis by Chawla et al reporting an overall median growth rate of 0.28cm/year [6]. Some 
tumours however will behave more aggressively and at present it is not possible to 
determine in advance which tumours these are. Nephron sparing surgery (NSS) represents 
the gold standard for the small renal mass and radical surgery for the T2 and larger 
tumours. 
Although laparoscopic nephron sparing surgery has been demonstrated to be both feasible 
and oncologically equivalent to open nephron sparing surgery it is widely acknowledged to 
be technically demanding with a steep learning curve and associated morbidity. This 
particularly relates to keeping warm ischaemia time to a minimum. In one of the largest 
series Gill et al reported a median surgical time of 3 hours and a median warm ischemia 
time of 27.8 minutes [7]. Although robotically assisted partial nephrectomy is gaining 
acceptance, active surveillance and minimally invasive alternatives including ablative 
techniques have emerged as alternatives to nephron sparing surgery or radical 
nephrectomy. 
The main ablative techniques in clinical use are cryotherapy and radiofrequency ablation. 
Cryotherapy is more frequently applied laparoscopically and radiofrequency ablation 
percutaneously. In some institutions including the Cleveland Clinic selected tumours are 
preferentially treated with minimally ablative techniques rather than with partial 
nephrectomy [8]. In addition other emerging techniques that have been described include 
High Intensity Focused Ultrasound, Microwave thermotherapy, Interstitial Laser ablation 
and CyberKnife. Whilst there is increasing evidence in support of radiofrequency ablation 
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and cryotherapy, there is less clear evidence in support of the other minimally invasive 
techniques at present. 
2. Cryotherapy 
Tissue destruction by freezing and thawing has been used in a variety of medical problems 
for over 150 years with minimal clinical significance. However, with the development of 
vacuum-insulated liquid nitrogen and argon cooled probes, a real breakthrough was made 
and targeted cryoablation of renal tumours became a reality. Currently cryoablation is 
performed using an argon gas based system which operates on the Joule- Thompson 
principle (i.e., rapid cooling of the tip of a probe by highly compressed liquid nitrogen or 
argon expanding through a restricted orifice to the gaseous state). Using this principle, very 
low temperatures of – 1750C to – 1900C can be focused on to kidney tissue to freeze tumours. 
Based on the same principle helium gas can be used for thawing [9]. Cryoprobes of varying 
diameters are now available and they produce ice balls of varying shapes [10]. 
3. Mechanism of cryoablation 
Although the exact mechanism of tissue injury resulting from freezing is not completely 
understood, experimental studies have provided us with a fair knowledge of the mode of 
action of cryotherapy. The physiological changes of freezing are described as acute and 
delayed. When the tissues are exposed to temperature of -50C, ice is formed in the 
extracellular space. This changes the osmotic gradient and draws water from the 
intracellular to the extracellular compartment, leading to changes, in the intracellular solute 
composition, pH and eventually leads to protein denaturation [11,12]. When the 
temperature reaches to -200C, ice forms both intra and extracellularly. It is believed that 
the intracellular ice shears the cell membrane with irreversible cell damage. Complete 
destruction of normal renal parenchyma occurs at temperatures below -19.4 0C [13, 14]. 
Delayed tissue injury also occurs after cryoablation. This is due to damage to the 
microvasculature of the target tissue and formation of microthrombi. This phenomenon 
leads to delayed cell death and is believed to be the significant mechanism of action of 
cryotherapy [15]. Tissue destruction is achieved better by the combination of freezing and 
thawing processes. Double freezing, as compared to a single- freeze approach, has been 
shown to produce large areas of necrosis in animal models with significantly increased 
cell death [16]. 
4. Indications and contraindications for renal cryotherapy 
The indications for cryotherapy are the same as that for partial nephrectomy. A peripherally 
situated, enhancing, well- circumscribed tumour which is less than 4cm is the ideal lesion 
for cryotherapy. In general younger patients are offered partial nephrectomy. In older 
patients or those with comorbidities such as diabetes, hypertension, congestive cardiac 
failure cryotherapy is considered. In certain special situations such as tumour less than 4cms 
in solitary or transplant kidney; hereditary conditions such as Von Hippel- Lindau disease 
and tuberous sclerosis, cryotherapy may be ideal [17]. 
The relative contraindications for cryotherapy are young age, tumours greater than 4cms, 
hilar tumours, intrarenal tumours, and cystic tumours. The only absolute contraindication is 
untreatable or irreversible coagulopathy [18]. 
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5. Technique of cryotherapy 
Most patients are treated with laparoscopic or percutaneous image guided minimally 
invasive techniques. Open cryotherapy may occasionally be necessary and is also described. 
6. Laparoscopic cryotherapy 
Tumours that are situated in the anterior aspect of kidney and in the polar region are ideally 
treated by a transperitoneal laparoscopic technique and the posterior tumours by the 
retroperitoneal approach. The transperitoneal technique that we use is as follows: 
 
 
Fig. 1. Showing kidney tumour treated with argon gas cryotherapy- note the spectacular 
freezing of the tumour. 
After placing the ports, the kidney is well mobilised. Gerota’s fascia is incised and the 
perirenal fat is dissected from the surface of the kidney. The exophytic tumour is well seen 
at this stage and is defined. The position and the depth of the tumour are confirmed and 
measured using a laparoscopic ultrasound probe. Two to three good core biopsies are taken 
for histology. Cryoprobes are then placed perpendicularly into the tumour with the tip 
extending about 5mm beyond. The number of probes placed is determined by the size of the 
tumour. Two thermosensors are placed one in the centre of the lesion and the other beyond 
the margin of the tumour to monitor the temperature during cryoablation. The cryoablation 
starts with a freeze cycle with delivery of the argon gas through the probes. The cryolesion 
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is readily visible as an ice ball and visible in the ultrasound. Typically the first freeze cycle is 
for 10 minutes. The target temperature in the centre of the lesion is -400C and below. This is 
followed by a thaw cycle with helium gas. Like many other centres we follow a two freeze 
and two thaw cycle protocol. At the end of the procedure, a passive and an active thaw are 
performed and then the probes are removed slowly, after the ice has fully melted. Retrieval 
of the probes should not be attempted if any resistance is noted as it may lead to fracture of 
the tumour. In this situation continuing passive thaw for some time allows easy removal of 
the probes (Fig 1) 
7. Percutaneous image-guided cryoablation 
Most cryoablations are performed under CT and MRI guidance. Tumours situated in the 
posterior and inferior aspect of the kidneys are ideal for image guided cryoablation. The 
upper pole tumours are difficult to reach. The procedure of cryotherapy is essentially 
similar to laparoscopic techniques. The advantages of percutaneous techniques are short 
hospital stay, ice ball monitoring by cross- sectional imaging, decreased analgesic 
requirement and lower cost compared to laparoscopy. Currently however, only 25% of 
tumours are treated by percutaneous image guided cryoablation and the techniques are still 
evolving [19]. 
8. Success and follow up 
The absence of enhancement in a post contrast CT-scan at three months following 
cryoablation is considered as a successful procedure. Although no algorithm exists the 
patients are closely followed with contrast CT- scans at six, nine and twelve months and 
ideally the tumour should show regression. Periodic long- term follow up should continue 
till the tumour is regressed completely and then annual surveillance to ensure that there is 
no recurrence from the margin. The presence of enhancement would indicate incomplete 
treatment. Rim enhancement only with no increase in size seems to occur commonly in the 
first few months after cryoablation and this usually settles. This usually is not an indication 
for biopsies as it is difficult to take and the yield is low [20]. A recent study from the 
Cleveland clinic concluded that biopsies did not provide sufficient additional information to 
contrast enhanced MRI or CT findings in the six months post treatment period and hence 
did not recommend biopsies [21]. 
9. Results 
The accumulating medium and long term data suggests that cryoablation is associated with 
high efficacy and low morbidity. The oncological control seems to be promising. The recent 
review by Berger and associates indicated a five and 10- year cancer specific survival of 93% 
and 81% respectively [22]. A meta-analysis showed that local recurrence (treatment failure) 
ranges from 4.6% to 5.2% and metastatic progression ranged from 1% to 1.2% [23]. 
10. Complications 
Cryotherapy is a minimally invasive treatment modality which ablates the renal tumour in 
situ. Although, it is reasonably safe it has a few complications. Minor renal laceration and 
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bleeding from the needle site is common but settles with pressure. Renal fracture and 
haemorrhage can be avoided by perpendicular placement of the cryoprobes and waiting for 
complete thawing before removing the probes. The area of skin surrounding the cryoprobes 
needs to be protected, by warm gauze, to prevent cold injury to the skin. The adjacent 
internal organs also need protection from cryo injury. Pancreatic injury and ureteropelvic 
junction stricture has been reported [24]. Data from a retrospective multi centre study for 
139 patients revealed that the major and minor complication rates associated with 
cryoablation were 1.8% and 9.2% respectively. The five major complications were ileus, 
haemorrhage, conversion to open surgery, scarring with ureteropelvic junction obstruction 
and urinary leakage. Overall, the most common complication as well as the most common 
minor complication was pain or paraesthesia at the probe insertion site [25]. 
11. Conclusions 
Renal cryotherapy has proven its safety with good oncological control at medium term with 
some long term data. Currently the main application of cryotherapy in kidney tumours is 
for peripheral lesions less than 4cm in patients who would benefit from or require nephron 
sparing surgery but are not candidates because of comorbidity. Laparoscopic cryotherapy is 
also on the rise in patients with normal kidneys and relatively normal fitness. The 
percutaneous approach is constantly evolving and the field is very promising. We have to 
wait for the long term oncological data but it appears that cryotherapy is here to stay. 
12. Radiofrequency ablation 
First used in the targeted destruction of hepatic lesions radiofrequency ablation (RFA) has 
been used since the 1990s. It was first used in the kidney in 1997 [26]. Many of the treatment 
protocols in RFA are derived from the liver experience. 
Although, it can be deployed laparoscopically it is most commonly applied percutaneously 
by interventional radiologists. The technique involves the insertion of 2 electrodes into the 
target tissue, in this case a renal tumour and conversion of electrical current between the 
two electrodes to ultrahigh (radio) frequency. This in turn ablates the intervening tissue 
with a margin of surrounding normal tissue. The mechanism of tissue destruction is 
immediate cellular damage and delayed microvascular impairment with the denaturation of 
proteins and the coagulation of tissue and the disruption of lipid cell membranes. The tissue 
needs to be heated to a temperature range of 50 to 100‘C [27,28]. Over 105’C, the heat 
distribution and so tissue destruction becomes patchy and unreliable. 
Real time imaging of RFA with intra operative USS CT or MRI has proved to be unreliable 
because of the similarity between normal and ablated tissue and because of the formation of 
gas bubble artefact. As a result imaging is usually confined to assisting initial probe 
placement with the RFA being monitored by temperature and or impedance changes. 
The advantages of this minimally invasive technique include the ability to apply the energy 
percutaneously under light sedation, avoiding a general anaesthetic and allowing a more 
rapid recovery with low morbidity. 
The disadvantages of the technique include a lower success rate compared to cryotherapy or 
nephron sparing surgery. In addition there are only short to medium term results available 
and the long term efficacy is not established. Also a significant proportion of the reported 
studies did not establish histological confirmation of a tumour before treatment and so 
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histological confirmation of successful ablation or cure is problematic. It is difficult to 
interpret the results if it is not certain that the original lesion was malignant. Furthermore as 
the natural history of the small renal mass is still not completely clear it may be that a 
significant proportion of the lesions that are tumours would have followed an indolent 
course without treatment and that the application of an ablative technique is an over 
treatment. As with cryotherapy, proximity to large vessels may lead to the draining of 
ablative energy by conduction that in turn reduces efficacy of the procedure. Another 
challenge is confirmation of successful ablation or cure. Most series report biopsy of the 
lesion at 6 months together with serial imaging with CT, usually at 6 monthly intervals. A 
successful outcome is taken as a lack of contrast enhancement of the lesion on CT. In 
addition the lesion should show progressive shrinking on subsequent imaging. 
13. Results 
Early experience has shown promising short and medium term tumour control [29]. 
McDougal et al [30] have reported on patients with over 4 years follow-up and showed 
successful ablation of exophytic masses smaller than 5cm in diameter. 13 masses in 11 
patients with a mean tumour size 3.2cm were followed over a mean of 4.6 years. 12 (92.3%) 
of the 13 masses treated showed compete ablation. 
Zagoria et al [31] reported a retrospective series of 125 treated tumours in which 116 (93%) 
were completely ablated with a mean follow up of 13.8 months. All 95 tumours smaller than 
3.7cm were completely ablated and 21 (70%) of 30 larger tumours were completely ablated 
with 9 showing evidence of residual viable tumour on follow-up scans. They reported that 
with each 1cm increase in tumour diameter over 3.6cm the likelihood of tumour free 
survival decreased by a factor of 2.19 (p<0.001). There were 8 (8%) complications none of 
which resulted in long-term morbidity. 
Stern reported with a mean follow up of 30 months that RFA had the same outcome as 
partial nephrectomy for T1a lesions with a disease specific survival of 93.4% [32]. Levinson 
described over a period of at least 40 months a recurrence free survival of 90.3% in patients 
undergoing RFA for SRM in a single kidney [33]. 
There are concerns regarding the reliability of imaging to assess treatment response. Lack of 
enhancement of an ablated mass on CT does not always correlate with histological 
confirmation of no viable tumour tissue on biopsy. Weight reported that over 45% of renal 
tumours that showed no enhancement following RFA demonstrated viable tumour on 
biopsy at 6 months [34]. Others however have suggested that the presence of tumour on 
biopsy less than 12 months post treatment may be unreliable and have shown no viable 
tumour in 20 lesions that were biopsied over 12 months following treatment [35]. Where 
recurrences or cases of persistent disease do occur they tend to be demonstrated within 12 
months of treatment. In one study from several institutions 92.1% of renal tumour 
recurrences were detectable 12 months or fewer after ablation [36].  
One study reported the presence of pathological skip areas where tissue remains that has 
not been ablated. In this study this was found in seven of nine treated renal tumours [37]. 
A meta-analysis examining 47 studies comparing RFA and cryoablation for SRM has been 
published [38]. No differences were detected between the modalities in patient age, tumour 
size or follow-up. Pre-treatment biopsy was performed more often for lesions treated with 
cryoablation (82.3%) than with RFA (62.2%) (p<0.0001). There was a significantly higher rate 
of unknown pathology in lesions treated with RFA (40.4%) compared to those treated with 
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cryoablation (24.5%) (p<0.0001). Repeat ablation was more frequently performed after RFA 
(8.5%) than after cryoablation (1.3%) (p<0.0001) and the rate of local tumour progression 
was significantly higher for RFA (12.9%) than for cryoablation (5.2%) (p<0.0001). Metastasis 
was reported more frequently for RFA (2.5%) than for cryoablation (1%) (p=0.06). 
The authors of this large meta-analysis concluded that ablation of SRMs is a viable strategy 
based on short term oncological outcomes and that cryoablation results in fewer 
retreatments and improved local tumour control and may be associated with a lower risk of 
metastatic progression compared with RFA. 
A further meta-analysis by the same authors looked at all studies reporting on the 
management of SRMs whether by open or laparoscopic partial nephrectomy, RFA, 
cryoablation or observation [39]. The analysis included 99 studies involving 6471 renal 
masses. Local recurrence was reported in 2.6% of masses treated with partial nephrectomy, 
4.6% of cases treated with cryotherapy and 11.7% of masses treated with RFA. 
Morbidity although low includes perinephric haematomas, bile and urinary fistulae, 
pancreatic pseudocysts and a ureteric stricture [40, 41]. 
14. Conclusions 
Tumours most suitable for RFA are the same as those most suitable for nephron sparing 
surgery, that is those <3.5cm in diameter, peripheral, solid, exophytic lesions and away from 
the renal hilum and collecting system. 
In addition RFA may be recommended for patients with conditions predisposing them to 
repeated development of renal tumours requiring multiple treatments such as Von Hippel 
Lindau disease. 
A number of series have been reported with short and medium term follow up. The results 
appear to depend upon the position of the tumour with small exophytic peripheral tumours 
responding better than central lesions. 
Although the majority of incomplete ablations are apparent by 12 months ongoing 
surveillance imaging much the same as following partial nephrectomy is recommended.  
What remains to be seen is whether focal ablation actually alters the natural history of the 
small renal mass or whether the encouraging short and intermediate results are a function of 
the favourable nature of the lesion. 
15. High Intensity Focused Ultrasound (HIFU) 
HIFU is very attractive as a completely non-invasive treatment option. The focused 
ultrasound beam has a thermal and a cavitational effect. The thermal effect is caused by the 
absorption of ultrasonic sound waves by the tissues resulting in protein denaturation and 
coagulative necrosis [42]. The cavitation effect is caused by bubble implosion leading to 
mechanical disruption. 
The first feasibility study was reported by Vallencien in 1993 [43] who found evidence of 
ablation in 8 patients with renal tumours. The limitations of the technique include difficulty 
in lesion localisation and targeting, small ablation zones and side effects including bowel 
injury and skin burns. In addition, in renal tumours the overlying ribs and respiratory 
movements can present a problem [44]. 
One study applied HIFU to the healthy renal tissue of patients requiring nephrectomy for 
tumour and found the tissue effects were variable and did not correspond well with the 
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amount of HIFU energy applied [45]. Other studies have also not demonstrated complete 
tumour ablation [46, 47]. At present therefore, HIFU although very attractive is not 
recommended as a treatment option. 
16. Microwave thermotherapy 
Microwave thermotherapy involves the insertion of flexible antennae into tissue and the 
formation of a rapidly alternating electromagnetic field which in turn causes coagulative 
necrosis [48]. Experimental studies in rabbits have suggested oncological equivalence with 
nephrectomy [49]. 
The disadvantages of the limited zone of ablation and the large antenna size have limited 
the minimally invasive application of microwave thermotherapy. The technique remains 
largely experimental although some early clinical experience has been described [50, 51]. 
The technique has also been described as an adjunct to open partial nephrectomy in order to 
provide a bloodless plane before resection [52].  
17. Interstitial LASER coagulation 
Interstitial LASER therapy works by inserting a bare-tip laser fibre directly into tissue. Laser 
light is converted to heat >55’C and causes tissue necrosis. Nd-YAG and diode lasers have 
been used. Although the technique has been described experimentally with the laparoscopic 
approach [53] and in a small number of clinical studies [54] it should still be regarded as 
experimental. 
18. Cyberknife (radiosurgery) 
This technique was pioneered in neurosurgery for the treatment of intracranial tumours and 
uses stereotactic techniques to apply highly focused radiation. The cyberknife is a frameless 
image-guided radiosurgery device with a linear accelerator on a robotic arm which delivers 
an adequate conformal dose of radiation by focusing a large number of radiation beams at 
the target area such that each individual beam does not damage the surrounding normal 
tissue. Ponsky et al reported initial results in porcine kidneys and demonstrated complete 
fibrosis of the lesions with preservation of the surrounding normal tissue [55]. A phase 1 
study of radiosurgery involving 3 patients showed necrotic tumour in 1 of the 3 patients at 
subsequent nephrectomy and further trials are awaited [56]. 
19. Conclusion 
In this chapter we have discussed the management of small renal tumours by ablative 
therapies. These treatments have emerged as an alternative to nephron sparing or radical 
surgery. The most common ablative techniques are cryotherapy and radiofrequency 
ablation (RFA). The indications for ablative techniques are the same as for partial 
nephrectomy and the ideal lesion is a peripheral, enhancing, well circumscribed lesion less 
than 4cm in diameter (Fig2) 
Cryotherapy is most commonly applied laparoscopically and depends upon repeated freeze 
thaw cycles to achieve tissue destruction. There is good oncological control in the medium 
term and long term data is continuing to emerge. 
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Radiofrequency ablation is more commonly applied percutaneously. Several meta-analyses 
have suggested that short term oncological outcomes are good but that local recurrence, 
retreatment rates and progression to metastatic disease may be higher than with 
cryotherapy. 
Other ablative techniques include High Intensity Focused Ultrasound (HIFU), Microwave 
Thermotherapy, Interstitial Laser Coagulation and Radiosurgery (Cyberknife). Although 
attractive as treatment options these techniques are yet to be established as viable treatments 
for the small renal mass. 
 
 
Fig. 2. The Management of Small Renal Tumours by Ablative Therapies 
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